Literature DB >> 22340268

Catheter-deliverable hydrogel derived from decellularized ventricular extracellular matrix increases endogenous cardiomyocytes and preserves cardiac function post-myocardial infarction.

Jennifer M Singelyn1, Priya Sundaramurthy, Todd D Johnson, Pamela J Schup-Magoffin, Diane P Hu, Denver M Faulk, Jean Wang, Kristine M Mayle, Kendra Bartels, Michael Salvatore, Adam M Kinsey, Anthony N Demaria, Nabil Dib, Karen L Christman.   

Abstract

OBJECTIVES: This study evaluated the use of an injectable hydrogel derived from ventricular extracellular matrix (ECM) for treating myocardial infarction (MI) and its ability to be delivered percutaneously.
BACKGROUND: Injectable materials offer promising alternatives to treat MI. Although most of the examined materials have shown preserved or improved cardiac function in small animal models, none have been specifically designed for the heart, and few have translated to catheter delivery in large animal models.
METHODS: We have developed a myocardial-specific hydrogel, derived from decellularized ventricular ECM, which self-assembles when injected in vivo. Female Sprague-Dawley rats underwent ischemia reperfusion followed by injection of the hydrogel or saline 2 weeks later. The implantation response was assessed via histology and immunohistochemistry, and the potential for arrhythmogenesis was examined using programmed electrical stimulation 1 week post-injection. Cardiac function was analyzed with magnetic resonance imaging 1 week pre-injection and 4 weeks post-MI. In a porcine model, we delivered the hydrogel using the NOGA-guided MyoStar catheter (Biologics Delivery Systems, Irwindale, California), and utilized histology to assess retention of the material.
RESULTS: We demonstrate that injection of the material in the rat MI model increases endogenous cardiomyocytes in the infarct area and maintains cardiac function without inducing arrhythmias. Furthermore, we demonstrate feasibility of transendocardial catheter injection in a porcine model.
CONCLUSIONS: To our knowledge, this is the first in situ gelling material to be delivered via transendocardial injection in a large animal model, a critical step towards the translation of injectable materials for treating MI in humans. Our results warrant further study of this material in a large animal model of MI and suggest this may be a promising new therapy for treating MI.
© 2012 American College of Cardiology Foundation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22340268      PMCID: PMC3285410          DOI: 10.1016/j.jacc.2011.10.888

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  69 in total

1.  Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution.

Authors:  R J Laham; M Rezaee; M Post; F W Sellke; R A Braeckman; D Hung; M Simons
Journal:  Drug Metab Dispos       Date:  1999-07       Impact factor: 3.922

Review 2.  Mechanisms and models in heart failure: A combinatorial approach.

Authors:  D L Mann
Journal:  Circulation       Date:  1999-08-31       Impact factor: 29.690

Review 3.  Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering.

Authors:  M P Lutolf; J A Hubbell
Journal:  Nat Biotechnol       Date:  2005-01       Impact factor: 54.908

Review 4.  Custom design of the cardiac microenvironment with biomaterials.

Authors:  Michael E Davis; Patrick C H Hsieh; Alan J Grodzinsky; Richard T Lee
Journal:  Circ Res       Date:  2005-07-08       Impact factor: 17.367

5.  Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis.

Authors:  D Aviezer; D Hecht; M Safran; M Eisinger; G David; A Yayon
Journal:  Cell       Date:  1994-12-16       Impact factor: 41.582

Review 6.  Perlecan: a gem of a proteoglycan.

Authors:  R V Iozzo
Journal:  Matrix Biol       Date:  1994-04       Impact factor: 11.583

7.  Catheter-based transendocardial delivery of autologous bone-marrow-derived mononuclear cells in patients listed for heart transplantation.

Authors:  Guilherme V Silva; Emerson C Perin; Hans F R Dohmann; Radovan Borojevic; Suzana A Silva; Andre L S Sousa; Joao A R Assad; William K Vaughn; Claudio T Mesquita; Luciano Belém; Antonio C Carvalho; Hans J F Dohmann; Ellen Barroso do Amaral; Joaquim Coutinho; Rodrigo Branco; Edie Oliveira; James T Willerson
Journal:  Tex Heart Inst J       Date:  2004

8.  Human perlecan immunopurified from different endothelial cell sources has different adhesive properties for vascular cells.

Authors:  J M Whitelock; L D Graham; J Melrose; A D Murdoch; R V Iozzo; P A Underwood
Journal:  Matrix Biol       Date:  1999-04       Impact factor: 11.583

Review 9.  Graft-versus-host disease and the Th1/Th2 paradigm.

Authors:  W Krenger; J L Ferrara
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

10.  Fibulin is an extracellular matrix and plasma glycoprotein with repeated domain structure.

Authors:  W S Argraves; H Tran; W H Burgess; K Dickerson
Journal:  J Cell Biol       Date:  1990-12       Impact factor: 10.539

View more
  119 in total

1.  Injectable skeletal muscle matrix hydrogel promotes neovascularization and muscle cell infiltration in a hindlimb ischemia model.

Authors:  Jessica A DeQuach; Joy E Lin; Cynthia Cam; Diane Hu; Michael A Salvatore; Farah Sheikh; Karen L Christman
Journal:  Eur Cell Mater       Date:  2012-06-05       Impact factor: 3.942

Review 2.  Extracellular Matrix and Regenerative Therapies from the Cardiac Perspective.

Authors:  Arin Dogan; Mahmut Parmaksız; A Eser Elçin; Y Murat Elçin
Journal:  Stem Cell Rev Rep       Date:  2016-04       Impact factor: 5.739

Review 3.  Cardiovascular tissue bioprinting: Physical and chemical processes.

Authors:  James B Hu; Martin L Tomov; Jan W Buikema; Caressa Chen; Morteza Mahmoudi; Sean M Wu; Vahid Serpooshan
Journal:  Appl Phys Rev       Date:  2018-12       Impact factor: 19.162

4.  In vivo testing of an injectable matrix gel for the treatment of shoulder cuff muscle fatty degeneration.

Authors:  Tai Huynh; John Taehwan Kim; Grady Dunlap; Shahryar Ahmadi; Jeffrey C Wolchok
Journal:  J Shoulder Elbow Surg       Date:  2020-06-09       Impact factor: 3.019

5.  Injectable Hydrogels with In Situ Double Network Formation Enhance Retention of Transplanted Stem Cells.

Authors:  Lei Cai; Ruby E Dewi; Sarah C Heilshorn
Journal:  Adv Funct Mater       Date:  2015-03-04       Impact factor: 18.808

Review 6.  Cardiac fibrosis: potential therapeutic targets.

Authors:  Shuin Park; Ngoc B Nguyen; Arash Pezhouman; Reza Ardehali
Journal:  Transl Res       Date:  2019-03-09       Impact factor: 7.012

7.  Delivery of an engineered HGF fragment in an extracellular matrix-derived hydrogel prevents negative LV remodeling post-myocardial infarction.

Authors:  Sonya B Sonnenberg; Aboli A Rane; Cassie J Liu; Nikhil Rao; Gillie Agmon; Sophia Suarez; Raymond Wang; Adam Munoz; Vaibhav Bajaj; Shirley Zhang; Rebecca Braden; Pamela J Schup-Magoffin; Oi Ling Kwan; Anthony N DeMaria; Jennifer R Cochran; Karen L Christman
Journal:  Biomaterials       Date:  2015-01-13       Impact factor: 12.479

8.  Controlling stem cell behavior with decellularized extracellular matrix scaffolds.

Authors:  Gillie Agmon; Karen L Christman
Journal:  Curr Opin Solid State Mater Sci       Date:  2016-08       Impact factor: 11.354

9.  Oxime cross-linked injectable hydrogels for catheter delivery.

Authors:  Gregory N Grover; Rebecca L Braden; Karen L Christman
Journal:  Adv Mater       Date:  2013-03-12       Impact factor: 30.849

10.  Safety and efficacy of an injectable extracellular matrix hydrogel for treating myocardial infarction.

Authors:  Sonya B Seif-Naraghi; Jennifer M Singelyn; Michael A Salvatore; Kent G Osborn; Jean J Wang; Unatti Sampat; Oi Ling Kwan; G Monet Strachan; Jonathan Wong; Pamela J Schup-Magoffin; Rebecca L Braden; Kendra Bartels; Jessica A DeQuach; Mark Preul; Adam M Kinsey; Anthony N DeMaria; Nabil Dib; Karen L Christman
Journal:  Sci Transl Med       Date:  2013-02-20       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.